Klaria Pharma (KLAR) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 reached 8.99 MSEK, a significant increase from 0.12 MSEK in Q1 2024, driven by licensing activities and project progress.

• Profit after tax improved to -1.6 MSEK from -11.9 MSEK year-over-year, reflecting higher revenues and reduced R&D costs.

• Signed a major license agreement with CNX Therapeutics for Sumatriptan Alginate Film in Europe, with upfront and milestone payments plus royalties.

• Focused on expanding licensing agreements outside Europe, especially targeting the US market.

Financial highlights

• Net sales: 8,985 TSEK (Q1 2025) vs. 123 TSEK (Q1 2024); full year 2024: 2,248 TSEK.

• R&D costs: 3,425 TSEK (Q1 2025) vs. 4,557 TSEK (Q1 2024); full year 2024: 22,105 TSEK.

• Profit after tax: -1,592 TSEK (Q1 2025) vs. -11,886 TSEK (Q1 2024); EPS: -0.01 SEK vs. -0.11 SEK.

• Cash flow from operating activities: 922 TSEK (Q1 2025) vs. -7,830 TSEK (Q1 2024).

• Cash and cash equivalents: 1,520 TSEK at period end (Q1 2025) vs. 919 TSEK (Q1 2024).

• Equity: 1,690 TSEK (Q1 2025) vs. 29,206 TSEK (Q1 2024); equity/assets ratio: 3% (Q1 2025) vs. 43% (Q1 2024).

Outlook and guidance

• Initial launch of Sumatriptan Alginate Film in Germany, Spain, and Italy planned for H2 2025, with further European expansion in 2026.

• Actively pursuing additional licensing agreements outside Europe, aiming for at least one more in 2025.

• US market entry targeted, with advisory partnership established to secure a marketing partner.